Publicaciones en las que colabora con Javier Montero Moreno (10)

2024

  1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

    Ophthalmology, Vol. 131, Núm. 6, pp. 708-723

  2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1449-1458

2019

  1. Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN)

    Progress in Retinal and Eye Research, Vol. 69, pp. 80-115

2018

  1. Degeneración macular asociada a la edad (DMAE) atrófica

    s.n.

  2. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

2015

  1. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia six years outcome

    Retina, Vol. 35, Núm. 12, pp. 2450-2456

2011

  1. Myopic choroidal neovascularization

    Ophthalmology

2006

  1. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization

    Acta Ophthalmologica Scandinavica, Vol. 84, Núm. 6, pp. 743-748